Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

fondaparinux sodium

ARIXTRA

fondaparinux sodium (ARIXTRA) is a antithrombin-iii activator. Associated with BRIGHT MINDS BIOSCIENCES INC.. Route of administration: subcutaneous. Current US regulatory status: approved.

FDA: approved EMA: approved Blood and blood forming organs (B01) B01AX05
US status approved
Patents linked 20
Pipeline programs 0
News articles 0
Drug details — fondaparinux sodium
US status
approved
Class
Blood and blood forming organs (B01)
Route
SUBCUTANEOUS
Patents
20
Programs
0
Data quality
0.89
← All drugs Manufacturer profile Related patents Drug news hub Event calendar

Quick answer

fondaparinux sodium (ARIXTRA) is a antithrombin-iii activator. Associated with BRIGHT MINDS BIOSCIENCES INC.. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN fondaparinux sodium
Brand ARIXTRA
Mechanism Antithrombin-III activator
Target Antithrombin-III
Therapeutic class Blood and blood forming organs (B01)
Route SUBCUTANEOUS
Formulation SOLUTION
ATC code B01AX05
Originator BRIGHT MINDS BIOSCIENCES INC.

Mechanism of action

Antithrombin-III activator

Primary target: Antithrombin-III

Approval history

Authority Status Date
FDA approved —
EMA approved —

Related & competitor drugs

Browse all drugs
  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Related patents

Browse patents BRIGHT MINDS BIOSCIENCES INC. patent hub

  1. US 12350120

    Gum-protecting and teeth-whitening strip and preparation method thereof

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12220447

    Proteolytic enzyme composition

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12215133

    GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12097230

    Method and composition for treating post operative conditions

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11647776

    Extract, consumable product and method for enriching bioactive metabolite in an extract

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11642323

    Method for modulating metabolism

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11382880

    Method for improving digestive health

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11191761

    SOMCL-9112 solid dispersion and preparation method thereof and SOMCL-9112 solid preparation containing SOMCL-9112 solid dispersion

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11173136

    Method for modulating metabolism

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11053286

    Stabilised FMDV capsids

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10946308

    Enzymatic method for extraction and purification of phytocannabinoids

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10689413

    Composition enriched in single isomer of NUC-1031 and preparation method and use thereof

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10294277

    Stabilised FMDV capsids

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10292940

    Hyaluronic acid-based amphiphilic polymer, preparation method and application thereof

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9969777

    Mutant spike protein extending the tissue tropism of infectious bronchitis virus (IBV)

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9243230

    Construct for producing empty virus capsids

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8828407

    Chimaeric protein

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8507463

    Nucleotide analogue prodrug and the preparation thereof

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7935714

    Compositions for sleeping disorders

    Expires Mon Apr 28 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7270994

    Lactobacillus casei Bd-II stain and used to reduce blood cholesterol

    Expires Mon Sep 13 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is fondaparinux sodium?

fondaparinux sodium (ARIXTRA) is a antithrombin-iii activator. Associated with BRIGHT MINDS BIOSCIENCES INC.. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for fondaparinux sodium?

ARIXTRA is a marketed brand name for fondaparinux sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of fondaparinux sodium?

fondaparinux sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.